A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma (original) (raw)

• Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;15:1359–64
  Article CAS Google Scholar
• Parangi S, O’Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A 1996;93:2002–7
  Article PubMed CAS Google Scholar
• Investigator’s brochure: recombinant humanized anti-VEGF antibody (rhuMAb VEGF; bevacizumab). August 14, 2000
• Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895–8
  Article PubMed CAS Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76
  Article PubMed CAS Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4–10
  Article PubMed CAS Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42
  Article PubMed CAS Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non–small cell cancer. J Clin Oncol 2004;22:2184–91
  Article PubMed CAS Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792–9
  Article PubMed CAS Google Scholar
• Dinney CP, Bilenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998;58:808–14
  PubMed CAS Google Scholar
• Sangfelt O, Erickson S, Castro J, et al. Molecular mechanisms underlying interferon-alpha–induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 1999;18:2798–810
  Article PubMed CAS Google Scholar
• Ezekowitz RA, Mulliken JB, Folkman J. Interferon alpha-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456–63
  Article PubMed CAS Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989;10:1–10
  Article PubMed CAS Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16
  Article PubMed CAS Google Scholar
• Kim CJ, Reintgen DS, Balch CM. The new melanoma staging system. Cancer Control 2002;9:9–15
  PubMed Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60–5
  Article PubMed CAS Google Scholar
• Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005;69(Suppl 3):25–33
  Article PubMed CAS Google Scholar
• Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006;24:1145–51
  Article PubMed CAS Google Scholar
• Kabbinavar FF, Jambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706–12
  Article PubMed CAS Google Scholar
• Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1 epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non–small-cell lung cancer. J Clin Oncol 2005;23:2544–5
  Article PubMed CAS Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti- vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–34
  Article PubMed CAS Google Scholar
• Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173–80
  Article PubMed CAS Google Scholar
• Hurwitz H, Kavvinavar F. Bevacizumab combined with standard fluoropyrimidine- based chemotherapy regimens to treat colorectal cancer. Oncology 2005;69(suppl 3):17–24
  Article PubMed CAS Google Scholar
• Bottasso B, Mari D, Coppola R, et al. Hypercoagulability and hyperfibrinolysis in patients with melanoma. Thromb Res 1996;81:345–52
  Article PubMed CAS Google Scholar
• Blackwell K, Hurwitz H, Lieberman G, et al. Circulating d-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004;101:77–82
  Article PubMed CAS Google Scholar
• Marcoval J, Moreno A, Graells J, et al. Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. J Cutan Pathol 1997;24:212–8
  Article PubMed CAS Google Scholar
• Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer 1997;76:930–4
  PubMed CAS Google Scholar
• Gorski DH, Leal AD, Goydos JS. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. J Am Coll Surg 2003;197:408–18
  Article PubMed Google Scholar
• Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69(Suppl 3):4–10
  Article PubMed CAS Google Scholar
• Lacal PM, Failla CM, Pagani E, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 2000;115:1000–7
  Article PubMed CAS Google Scholar
• Straume O, Akslen LA. Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 relate to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001;159:223–35
  PubMed CAS Google Scholar
• Ugurel S, Rappl G, Tilgen W, et al. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577–83
  PubMed CAS Google Scholar
• Oku T, Tjuvajev JG, Miyagawa T, et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma xenografts. Cancer Res 1998;58:4185–92
  PubMed CAS Google Scholar
• Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet- derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000;20:4932–8
  Google Scholar
• Li Y, Wang MN, Li H, et al. Active immunization against the vascular endothelial growth factor flk 1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002;195:1575–84. Erratum in: J Exp Med 2002; 196:557
  Article PubMed CAS Google Scholar
• Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002;8:1369–75
  Article PubMed CAS Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645–55
  PubMed CAS Google Scholar
• Tao J, Tu YT, Huag CZ, et al. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br J Dermatol 2005;153:715–24
  Article PubMed CAS Google Scholar
• Sun J, Blaskovich MA, Jain RK, et al. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 2004;64:3586–92
  Article PubMed CAS Google Scholar
• Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64:4931–41
  Article PubMed CAS Google Scholar
• Giantonio BJ, Catalano PJ, O’Dwyer PJ, Meropol NJ, Benson AB. Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group’s Study E3200. J Clin Oncol 2006; 24(18 Suppl):3538
  Google Scholar
• Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825–36
  Article PubMed CAS Google Scholar
• Chapman PB, Einhorn LH, Meyers ML, et al. Phase III randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745–51
  PubMed CAS Google Scholar
• Jansen B, Wacheck V, Heere-Rees, et al. Clinical, pharmacologic, and pharmacodynamic study of genasense (G3139, Bcl-2 antisense oligonucleotide) and dacarbazine (DTIC) in patients with metastatic melanoma. J Clin Oncol 2001; 20:1426
  Google Scholar